To view the PDF file, sign up for a MySharenet subscription.

SABVEST CAPITAL LIMITED - Termination of Sabcaps proposed indirect investment in Ascendis Medical through Apex

Release Date: 27/06/2022 17:49
Code(s): SBP     PDF:  
Wrap Text
Termination of Sabcap’s proposed indirect investment in Ascendis Medical through Apex

SABVEST CAPITAL LIMITED
Incorporated in the Republic of South Africa
Registration number 2020/030059/06
ISIN: ZAE000283511
JSE share code: SBP
("Sabcap")

TERMINATION OF SABCAP’S PROPOSED INDIRECT INVESTMENT IN ASCENDIS MEDICAL THROUGH APEX

Sabcap shareholders are referred to:

    •   The Sabcap announcement on 3 February 2022 released on the JSE Stock Exchange News
        Service (SENS) advising that Apex Partners Holdings (Pty) Limited (Apex), in which Sabcap has a
        44,8% interest, had provided debt refinancing to Ascendis Health Limited (Ascendis) in January
        2022 and had agreed to acquire the entities through which the business known as "Ascendis
        Medical" operates (the Medical Transaction).

    •   The Ascendis announcement released on SENS on 17 May 2022 advising that it had secured new
        debt facilities and had repaid existing debt providers including Apex.

    •   The Ascendis announcement released on SENS today advising that the Medical Transaction has
        been terminated.

Sabcap shareholders are advised that the debt repayment to Apex comprised all capital plus interest,
financial guarantees provided by Sabcap on behalf of Apex for a portion of the debt refinancing and the
Medical Transaction have been released, and the termination of the Medical Transaction was by mutual
agreement between the parties.

Sandton
27 June 2022

Sponsor
RAND MERCHANT BANK (A division of FirstRand Bank Limited)

Date: 27-06-2022 05:49:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story